<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3316">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340557</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-ARB</org_study_id>
    <secondary_id>2003902</secondary_id>
    <nct_id>NCT04340557</nct_id>
  </id_info>
  <brief_title>Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection</brief_title>
  <official_title>Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharp HealthCare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sharp HealthCare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to identify whether or not Angiotensin Receptor Blockers
      (ARB) can halt the progression to respiratory failure requiring transfer into the intensive
      care unit (ICU), as well as halt mechanical ventilation in subjects with mild to moderate
      hypoxia due to the corona virus that causes COVID-19. Based on previous animal studies, the
      researchers hypothesize that the addition of an ARB is beneficial in abating acute lung
      injury in subjects in early stages of SARS-CoV-2 viral induced hypoxia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator initiated, open label, multicenter, two arm, randomized study to
      compare the impact of adding an ARB to the Standard of Care (SOC) to the SOC without an ARB.
      Randomization ratio will be 1:1. The goal of this study is to identify whether or not ARBs
      have an impact on inhibiting the progression to respiratory failure requiring mechanical
      ventilation in patients with mild to moderate hypoxia in the setting of COVID-19. The
      addition of an ARB to the standard of care treatment for these patients may be beneficial in
      abating acute lung injury in patients in early stages of SARSCoV-2 induced hypoxia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized into one of two groups: Standard of Care or Standard of Care plus an ARB.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days</time_frame>
    <description>Number of subjects requiring transfer into ICU for mechanical ventilation due to respiratory failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU transfer</measure>
    <time_frame>from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days</time_frame>
    <description>Number of subjects transferred from non-ICU bed to an ICU bed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen therapy</measure>
    <time_frame>from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days</time_frame>
    <description>Number of days requiring oxygen therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Group A (Study drug+SOC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of Care plus an ARB to be taken orally twice daily for up to 10 days or until discharged from the hospital, whichever occurs first. Investigator may increase dose on days 2 - 10 if confident the subject will tolerate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (SOC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days.</description>
    <arm_group_label>Group A (Study drug+SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed COVID-19 positive test result

          -  Mild to moderate respiratory symptoms of COVID-19.

          -  Systolic blood pressure ≥ 105 mmHg.

          -  Screen within 3 days of a positive COVID-19 test.

          -  Age ≥18 years old.

          -  Access to a phone in the hospital room or an electronic device that is capable of
             receiving phone or video calls.

          -  Able to read/write/speak English or Spanish fluently.

          -  Subjects must have the capacity to provide consent or an appropriate LAR to provide
             informed consent.

          -  Negative pregnancy test for women of childbearing potential and subject is randomized
             to the study arm.

        Exclusion Criteria:

          -  Severe allergy to any ARB or ACE-inhibitor, including angioedema

          -  In the intensive care unit at screening.

          -  Home meds include any kind of ACE inhibitor or ARB

          -  Acute Kidney Injury (50% reduction in GFR from baseline at admission to any time
             during treatment in the study treatment arm)

          -  Hyperkalemia &gt;5.0 mmol/L at baseline or any time during treatment in the study
             treatment arm

          -  Creatinine Clearance &lt; 30 ml/min at baseline or any time during treatment in the study
             treatment arm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Sakoulas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sharp HealthCare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katie Miller</last_name>
    <phone>(858) 939-7162</phone>
    <email>kathryn.miller@sharp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cary Murphy, RN</last_name>
    <phone>(619)740-4363</phone>
    <email>cary.murphy@sharp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sharp Grossmont Hospital</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cary Murphy, RN</last_name>
      <phone>619-740-4363</phone>
      <email>cary.murphy@sharp.com</email>
    </contact>
    <contact_backup>
      <last_name>Adriana Valdez-Hernandez, RN</last_name>
      <phone>(619)458-2260</phone>
      <email>Adriana.Valdez-hernandez@sharp.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sharp Chula Vista Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cary Murphy, RN</last_name>
      <phone>619-740-4363</phone>
      <email>cary.murphy@sharp.com</email>
    </contact>
    <contact_backup>
      <last_name>Adriana Valdez-Hernandez, RN</last_name>
      <phone>(619)458-2260</phone>
      <email>Adriana.Valdez-hernandez@sharp.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sharp Coronado Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cary Murphy, RN</last_name>
      <phone>619-740-4363</phone>
      <email>Cary.Murphy@sharp.com</email>
    </contact>
    <contact_backup>
      <last_name>Adriana Valdez-Hernandez, RN</last_name>
      <phone>(619)458-2260</phone>
      <email>Adriana.Valdez-hernandez@sharp.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Geriak, PharmD</last_name>
      <phone>858-939-3717</phone>
      <email>matthew.geriak@sharp.com</email>
    </contact>
    <contact_backup>
      <last_name>Cary Murphy, RN</last_name>
      <phone>(619) 740-4363</phone>
      <email>cary.murphy@sharp.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sharp HealthCare</investigator_affiliation>
    <investigator_full_name>Matthew Geriak</investigator_full_name>
    <investigator_title>Investigational Pharmacist</investigator_title>
  </responsible_party>
  <keyword>Coronavirus</keyword>
  <keyword>Angiotensin receptor blocker</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

